Close

bluebird bio (BLUE) Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/23/2024

1. GM
2. TSLA
3. SPY
4. CPRI
5. NVDA
6. CDNS
7. ADBE
8. SPOT
9. JBLU
10. MTTR


Go back to bluebird bio (BLUE) Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease
BLUEBIRD BIO (NASDAQ: BLUE) Delayed: 0.95 --0 (-0%)
Previous Close $0.95    52 Week High $95.28 
Open $0.95    52 Week Low $35.37 
Day High $0.95    P/E N/A 
Day Low $0.95    EPS $-1.81 
Volume 3,924